7498 Results (Page 205 of 300)
Pharmaceuticals Markets Research Reports
US Age-Related Macular Degeneration Therapeutics Market Analysis
The US Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $4.536 Bn in 2022, and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to US $7.736 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others.
UK Age-Related Macular Degeneration Therapeutics Market Analysis
The UK Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $281 Mn in 2022 and is predicted to grow at a CAGR of 6.90% from 2023 to 2030, to US $479 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, advancements in treatment, and other factors. Major players in the industry include Regeneron Pharmaceuticals, Novartis, Bayer, Roche, Genentech, and other notable companies.
UAE Age-Related Macular Degeneration Therapeutics Market Analysis
The UAE Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $54 Mn in 2022 and is predicted to grow at a CAGR of 9.9% from 2023 to 2030, to US $115 Mn by 2030. The key drivers of this industry include the rising trend in the prevalence of age-related macular degeneration, the rapidly growing economy of the country, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Roche, Bayer, and Genetech, among others.
South Africa Age-Related Macular Degeneration Therapeutics Market Analysis
The South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $70 Mn in 2022 and is predicted to grow at a CAGR of 10.13% from 2023 to 2030, to US $152 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, expanding healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
UAE Depression Therapeutics Market Analysis
UAE depression therapeutics market is expected to grow from $51 Mn in 2022 to $82 Mn in 2030 with a CAGR of 6.2% for the forecasted year 2022-30. The growing awareness of depression and the supportive government initiatives to minimize the stigma associated with mental health disorders in the UAE are the major market drivers. The UAE depression therapeutics market is segmented by drug type, therapies, indication, and end users. Sahara Pharmaceutical, Viatris, and Allergan are the major players in the UAE depression therapeutics market.
Philippines Age-Related Macular Degeneration Therapeutics Market Analysis
The Philippines Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $24 Mn in 2022 and is predicted to grow at a CAGR of 9.40% from 2023 to 2030, to US $49 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, supportive government policies, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Singapore Age-Related Macular Degeneration Therapeutics Market Analysis
The Singapore Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $13 Mn in 2022, and is predicted to grow at (CAGR) of 9.50% from 2023 to 2030, to US $27 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, supportive government initiatives, and other factors. The industry is primarily dominated by players such as Roche, Regeneron Pharmaceuticals, Novartis, Bayer, and Genetech, among others
Saudi Arabia Age-Related Macular Degeneration Therapeutics Market Analysis
The Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $184 Mn in 2022, and is predicted to grow at a CAGR of 10.4% from 2023 to 2030, to US $405 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Mexico Age-Related Macular Degeneration Therapeutics Market Analysis
The Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $162 Mn in 2022 and is predicted to grow at (CAGR) of 9.15% from 2023 to 2030, to US $326 Mn by 2030. The key drivers of this industry include the surge in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others.
Malaysia Age-Related Macular Degeneration Therapeutics Market Analysis
The Malaysia Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $17 Mn in 2022, and is predicted to grow at (CAGR) of 9.10% from 2023 to 2030, to US $35 Mn by 2030. The key drivers of this industry include the rising trend in the prevalence of age-related macular degeneration, evolving healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Kenya Age-Related Macular Degeneration Therapeutics Market Analysis
The Kenya Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $8 Mn in 2022, and is predicted to grow at (CAGR) of 10% from 2023 to 2030, to US $16 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, evolving healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Japan Age-Related Macular Degeneration Therapeutics Market Analysis
The Japan Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $671 Mn in 2022, and is predicted to grow at a CAGR of 9.40% from 2023 to 2030, to US $1.377 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Indonesia Age-Related Macular Degeneration Therapeutics Market Analysis
The Indonesia Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $65 Mn in 2022, and is predicted to grow at a CAGR of 8.90% from 2023 to 2030, to US $128 Mn by 2030. The key drivers of this industry include the increased prevalence of age-related macular degeneration, evolving healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others.
Germany Age-Related Macular Degeneration Therapeutics Market Analysis
The Germany Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $395 Mn in 2022 and is predicted to grow at a CAGR of 7.10% from 2023 to 2030, to US $684 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, increased government spending, and other factors. The industry is primarily dominated by players such as Novartis, Bayer, Roche, Regeneron Pharmaceuticals, and Genetech, among others
France Age-Related Macular Degeneration Therapeutics Market Analysis
The France Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $297 Mn in 2022 and is predicted to grow at a CAGR of 7.90% from 2023 to 2030, to US $546 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, increased diagnosis and awareness, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
Egypt Age-Related Macular Degeneration Therapeutics Market Analysis
The Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $30 Mn in 2022 and is predicted to grow at a CAGR of 10.40% from 2023 to 2030, to US $67 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, a strong product pipeline, and other factors. The industry is primarily dominated by players such as Novartis, Bayer, Roche, Regeneron Pharmaceuticals, and Genetech, among others
China Age-Related Macular Degeneration Therapeutics Market Analysis
The China Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $0.86 Bn in 2022 and is predicted to grow at a CAGR of 10.40% from 2023 to 2030, to US $1.91 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, advancements in treatment, and other factors. Major players in the industry include Regeneron Pharmaceuticals, Novartis, Bayer, Roche, Genentech, and other notable companies
Brazil Age-Related Macular Degeneration Therapeutics Market Analysis
The Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $270 Mn in 2022 and is predicted to grow at a CAGR of 9.9% from 2023 to 2030, to US $575 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, the evolving healthcare landscape, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others
UAE Cardiovascular Diseases Therapeutics Market Analysis
UAE's cardiovascular disease therapeutics market is projected to grow from $813 Mn in 2022 to $1,530 Mn in 2030 with a CAGR of 8.22% for the year 2022-30. The rise in sedentary lifestyles adopted by the UAE citizens and the technological advancement of cardiovascular therapeutics in the UAE are responsible for the growth of the market. The UAE cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and end user. Lumitive, Hikma Pharmaceuticals, and F. Hoffmann-La Roche are the major players in the UAE cardiovascular disease therapeutics market.
UAE Cancer Immunotherapy Market Analysis
UAE's cancer immunotherapy market is expected to witness growth from $563 Mn in 2022 to $1,049 Mn in 2030 with a CAGR of 8.1% for the forecasted year 2022-30. The increasing incidence of cancer in the UAE along with favorable government initiatives to promote the use of immunotherapy treatment in the UAE are responsible for the growth of the market. The UAE cancer immunotherapy market is segmented by type, application, and end user. Lamba, Neopharma, and Bayer are the major players in the UAE cancer immunotherapy market.
UAE Acne Drugs Market Analysis
This report presents a strategic analysis of the UAE Acne Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the UAE Acne Drugs Market, offering unmatched value, accuracy, and expert insights.
Turkey Women's Health Market Analysis
This report presents a strategic analysis of the Turkey Women's Health Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Turkey Women's Health Market, offering unmatched value, accuracy, and expert insights.
Turkey Obesity Drugs Market Analysis
This report presents a strategic analysis of the Turkey Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Turkey Obesity Drugs Market, offering unmatched value, accuracy, and expert insights.
Turkey Lung Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Turkey Lung Cancer Therapeutics Market will reach a value of $462 Mn from $238 Mn in 2022, growing at a CAGR of 8.6% during 2022-30. The Lung Cancer Therapeutics Market in Turkey is dominated by a few domestic pharmaceutical companies such as Silanes, Liomont, and PISA. The Lung Cancer Therapeutics Market in Turkey is segmented into different types of cancer and different therapy types. Some of the major factors affecting the Turkey lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies, and the presence of highly efficient drugs.
Turkey Dialysis Market Analysis
This report presents a strategic analysis of the Turkey Dialysis Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Turkey Dialysis Market, offering unmatched value, accuracy, and expert insights.
